Table 2 Clinical tolerated doses of RNA-based medicines.
From: Next generation self-replicating RNA vectors for vaccines and immunotherapies
Name | Company | Bases | Formulation | ROA | Target | Highest dose reported with favorable safety profile | Ref |
|---|---|---|---|---|---|---|---|
mRNA-1893 | Moderna | Modified | Internal LNP | Intramuscular | Zika | 30 µg (interim reporting, 100 and 250 µg doses pending) | [85] |
VAL-506440; VAL-339851 | Moderna | Modified | Internal LNP | Intramuscular, Intradermal | Influenza | 100 µg (IM), 50 µg (ID) | |
mRNA-1273 | Moderna | Modified | Internal LNP | Intramuscular | SARS-CoV-2 | 100 µg | |
BNT162b2 | Pfizer/BioNTech | Modified | Acuitas LNP | Intramuscular | SARS-CoV-2 | 30 µg | |
CVnCoV | CureVac | Unmodified | Acuitas LNP | Intramuscular | SARS-CoV-2 | 12 µg | [91] |
ARCT-21 | Arcturus | Unmodified | Internal LNP | Intramuscular | SARS-CoV-2 | 7.5 µg | [14] |
LNP-nCoVsaRNA | ICL/VaxEquity | Unmodified | Internal LNP | Intramuscular | SARS-CoV-2 | 10 µg | [15] |
CORAL (BOOST) | Gritstone | Unmodified | Genevant LNP | Intramuscular | SARS-CoV-2 | 10 µg (interim reporting, 30 µg dose pending) | [92] |
MRT5500 | Translate Bio | Unmodified | Internal LNP | Intramuscular | SARS-CoV-2 | 45 µg (no DLTs reported) | |
CV7202 | CureVac | Unmodified | Acuitas LNP | Intramuscular | Rabies | 2 µg | [95] |
SLATE/GRANITE | Gritstone | Unmodified | Genevant LNP | Intramuscular | Neoantigens | 300 µg | [96] |
BI1361849 (CV9202) | CureVac | Unmodified | Protamine | Intramuscular | Prostate Cancer | 1920 µg | [97] |
MRT5005 | Translate Bio | Unmodified | Internal LNP | Nebulization | Cystic Fibrosis | SAD: 24 mg MAD: 16 mg | [37] |
